Udvalget for Humanmedicinske Lægemidler (CHMP) besluttede, at behandling med Replagal for patienter med Fabrys sygdom kunne give kliniske fordele på lang sigt.
The Committee for Medicinal products for Human Use (CHMP) decided that for patients with Fabry disease, treatment with Replagal might provide long-term clinical benefits.